SCHEMBL6490069

SCHEMBL6490069

CCOP(=O)(O)CC(=O)c1ccc(C)c(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.51
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
DUSP3 P51452 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPN11 Q06124 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
MTOR P42345 6/20 0.39
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3735124 0.81 PIM1 (0.44) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL5733074 0.80 L3MBTL1 (0.47) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL6490065 0.78 HPGD (0.51) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5733605 0.76 NPC1 (0.51) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20018287 0.75 HPGD (0.62) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2322449 0.75 HTR7 (0.47) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2322882 0.74 KMT2A (0.49) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2322311 0.74 SMN1; SMN2 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL5732716 0.74 KDM4E (0.45) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL5734845 0.74 POLB (0.57) HPGDALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 HPGD 692/4885ALDH1A1 569/4885MEN1 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.